Mortality in Adults with Hypopituitarism: a Systematic Review and Meta-analysis

Overview

Journal Endocrine

Specialty Endocrinology

Date 2016 Nov 7

PMID 27817141

Citations 43

Authors

Sina Jasim

Fares Alahdab

Ahmed T Ahmed

Shrikant Tamhane

Larry J Prokop

Todd B Nippoldt

M Hassan Murad

Affiliations

Soon will be listed here.

Abstract

Purpose: Hypopituitarism is a rare disorder with significant morbidity. To study the evidence on the association of premature mortality and hypopituitarism.

Methods: A comprehensive search of multiple databases: MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus was conducted through August, 2015. Eligible studies that evaluated patients with hypopituitarism and reported mortality estimates were selected following a predefined protocol. Reviewers, independently and in duplicate, extracted data and assessed the risk of bias.

Results: We included 12 studies (published 1996-2015) that reported on 23,515 patients. Compared to the general population, hypopituitarism was associated with an overall excess mortality (weighted SMR of 1.55; 95 % CI 1.14-2.11), I = 97.8 %, P = 0.000. Risk factors for increased mortality included younger age at diagnosis, female gender, diagnosis of craniopharyngioma, radiation therapy, transcranial surgery, diabetes insipidus and hypogonadism.

Conclusion: Hypopituitarism may be associated with premature mortality in adults. Risk is particularly higher in women and those diagnosed at a younger age.

Citing Articles

Long-Term IGF-1 Maintenance in the Upper-Normal Range Has Beneficial Effect on Low-Grade Inflammation Marker in Adults with Growth Hormone Deficiency.

Klinc A, Janez A, Jensterle M Int J Mol Sci. 2025; 26(5).

PMID: 40076636 PMC: 11900236. DOI: 10.3390/ijms26052010.

Sheehan syndrome: a current approach to a dormant disease.

Karaca Z, Kelestimur F Pituitary. 2025; 28(1):20.

PMID: 39863703 PMC: 11762620. DOI: 10.1007/s11102-024-01481-1.

Pituitary adenomas: biology, nomenclature and clinical classification.

Ho K, Melmed S Rev Endocr Metab Disord. 2025; .

PMID: 39862335 DOI: 10.1007/s11154-025-09944-x.

The oxytocin system in patients with craniopharyngioma: A systematic review.

Mann A, Kalitsi J, Jani K, Martins D, Kapoor R, Paloyelis Y Front Neuroendocrinol. 2024; 76:101170.

PMID: 39622476 PMC: 11904121. DOI: 10.1016/j.yfrne.2024.101170.

An Update on Advances in Hypopituitarism: Etiology, Diagnosis, and Current Management.

Iglesias P J Clin Med. 2024; 13(20).

PMID: 39458112 PMC: 11508259. DOI: 10.3390/jcm13206161.

References

McCallum R, Petrie J, Dominiczak A, Connell J . Growth hormone deficiency and vascular risk. Clin Endocrinol (Oxf). 2002; 57(1):11-24. DOI: 10.1046/j.1365-2265.2002.01559.x. View

Nilsson B, Bengtsson B, Jonsson B . Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival, and mortality. J Clin Endocrinol Metab. 2000; 85(4):1420-5. DOI: 10.1210/jcem.85.4.6498. View

Stochholm K, Gravholt C, Laursen T, Laurberg P, Andersen M, Kristensen L . Mortality and GH deficiency: a nationwide study. Eur J Endocrinol. 2007; 157(1):9-18. DOI: 10.1530/EJE-07-0013. View

Moher D, Liberati A, Tetzlaff J, Altman D . Reprint--preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Phys Ther. 2009; 89(9):873-80. View

Agha A, Sherlock M, Brennan S, OConnor S, OSullivan E, Rogers B . Hypothalamic-pituitary dysfunction after irradiation of nonpituitary brain tumors in adults. J Clin Endocrinol Metab. 2005; 90(12):6355-60. DOI: 10.1210/jc.2005-1525. View

Flickinger J, Nelson P, Taylor F, Robinson A . Incidence of cerebral infarction after radiotherapy for pituitary adenoma. Cancer. 1989; 63(12):2404-8. DOI: 10.1002/1097-0142(19890615)63:12<2404::aid-cncr2820631205>3.0.co;2-3. View

Haffner S, Stern M, Hazuda H, Rosenthal M, Knapp J, Malina R . Role of obesity and fat distribution in non-insulin-dependent diabetes mellitus in Mexican Americans and non-Hispanic whites. Diabetes Care. 1986; 9(2):153-61. DOI: 10.2337/diacare.9.2.153. View

Khaw K, Dowsett M, Folkerd E, Bingham S, Wareham N, Luben R . Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation. 2007; 116(23):2694-701. DOI: 10.1161/CIRCULATIONAHA.107.719005. View

Svensson J, Bengtsson B, Rosen T, Oden A, Johannsson G . Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J Clin Endocrinol Metab. 2004; 89(7):3306-12. DOI: 10.1210/jc.2003-031601. View

10.

Leonsson M, Hulthe J, Oscarsson J, Johannsson G, Wendelhag I, Wikstrand J . Intima-media thickness in cardiovascularly asymptomatic hypopituitary adults with growth hormone deficiency: relation to body mass index, gender, and other cardiovascular risk factors. Clin Endocrinol (Oxf). 2002; 57(6):751-9. DOI: 10.1046/j.1365-2265.2002.01663.x. View

11.

Irving R, Carson M, Webb D, Walker B . Peripheral vascular structure and function in men with contrasting GH levels. J Clin Endocrinol Metab. 2002; 87(7):3309-14. DOI: 10.1210/jcem.87.7.8655. View

12.

OHalloran D, Wieringa G, Tsatsoulis A, Shalet S . Increased serum lipoprotein(a) concentrations after growth hormone (GH) treatment in patients with isolated GH deficiency. Ann Clin Biochem. 1996; 33 ( Pt 4):330-4. DOI: 10.1177/000456329603300408. View

13.

Pfeifer M, Verhovec R, Zizek B, Prezelj J, Poredos P, Clayton R . Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. J Clin Endocrinol Metab. 1999; 84(2):453-7. DOI: 10.1210/jcem.84.2.5456. View

14.

Eden S, Wiklund O, Oscarsson J, Rosen T, Bengtsson B . Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations. Arterioscler Thromb. 1993; 13(2):296-301. DOI: 10.1161/01.atv.13.2.296. View

15.

Rosen T, Bengtsson B . Premature mortality due to cardiovascular disease in hypopituitarism. Lancet. 1990; 336(8710):285-8. DOI: 10.1016/0140-6736(90)91812-o. View

16.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

17.

Johansson J, Landin K, Tengborn L, Rosen T, Bengtsson B . High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults. Arterioscler Thromb. 1994; 14(3):434-7. DOI: 10.1161/01.atv.14.3.434. View

18.

van Bunderen C, van Nieuwpoort I, Arwert L, Heymans M, Franken A, Koppeschaar H . Does growth hormone replacement therapy reduce mortality in adults with growth hormone deficiency? Data from the Dutch National Registry of Growth Hormone Treatment in adults. J Clin Endocrinol Metab. 2011; 96(10):3151-9. DOI: 10.1210/jc.2011-1215. View

19.

Nielsen E, Lindholm J, Laurberg P, Bjerre P, Christiansen J, Hagen C . Nonfunctioning pituitary adenoma: incidence, causes of death and quality of life in relation to pituitary function. Pituitary. 2007; 10(1):67-73. DOI: 10.1007/s11102-007-0018-x. View

20.

Wieringa G, Toogood A, Ryder W, Anderson J, Mackness M, Shalet S . Changes in lipoprotein(a) levels measured by six kit methods during growth hormone treatment of growth hormone-deficient adults. Growth Horm IGF Res. 2001; 10(1):14-9. DOI: 10.1054/ghir.2000.0134. View